LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

BioNTech SE ADR

Fermé

SecteurSoins de santé

108.63 -1.29

Résumé

Variation du prix de l'action

24h

Actuel

Min

108.25

Max

110.29

Chiffres clés

By Trading Economics

Revenu

-747M

-445M

Ventes

-1B

183M

BPA

-1.821

Marge bénéficiaire

-243.654

Employés

6,772

EBITDA

-833M

-369M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+25.97% upside

Dividendes

By Dow Jones

Prochains Résultats

4 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

2B

27B

Ouverture précédente

109.92

Clôture précédente

108.63

Sentiment de l'Actualité

By Acuity

92%

8%

367 / 380 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

BioNTech SE ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

2 juin 2025, 11:48 UTC

Principaux Mouvements du Marché

BioNTech Sets Cancer-Drug Deal With Bristol Myers Potentially Worth More Than $11 Billion

4 févr. 2025, 18:52 UTC

Principaux Mouvements du Marché

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

15 nov. 2024, 10:28 UTC

Principaux Mouvements du Marché

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

20 mai 2025, 14:46 UTC

Acquisitions, Fusions, Rachats

Pfizer Is Jumping Into a Hot Cancer-Drug Race. It May Have Overpaid. -- Barrons.com

5 mai 2025, 15:13 UTC

Market Talk
Résultats

Narrower Guidelines for Covid-19 Booster Wouldn't Limit BioNTech's Customer Base Much -- Market Talk

15 nov. 2024, 11:14 UTC

Market Talk

U.S. Vaccine Stocks Fall After Trump Picks Vaccine Skeptic RFK Jr as Health Department Head-- Market Talk

15 nov. 2024, 10:34 UTC

Market Talk

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

5 août 2024, 10:02 UTC

Résultats

BioNTech Sees 2024 R&D Expenses EUR2.4B-EUR2.6B >BNTX

5 août 2024, 10:01 UTC

Résultats

BioNTech Backs 2024 View of Rev EUR2.5B-EUR3.1B >BNTX

5 août 2024, 10:01 UTC

Résultats

BioNTech: Invested EUR525.6M, or About 90% of 2Q R&D Spend, in Non-Covid-19 Related Activities >BNTX

5 août 2024, 10:00 UTC

Résultats

BioNTech 2Q-End Cash, Equivalents, Security Investments EUR18.5 Billion >BNTX

5 août 2024, 09:59 UTC

Résultats

BioNTech 2Q Loss EUR807.8M >BNTX

5 août 2024, 09:59 UTC

Résultats

BioNTech 2Q Loss/Shr EUR3.36 >BNTX

5 août 2024, 09:59 UTC

Résultats

BioNTech 2Q Rev EUR128.7M >BNTX

Comparaison

Variation de prix

BioNTech SE ADR prévision

Objectif de Prix

By TipRanks

25.97% hausse

Prévisions sur 12 Mois

Moyen 140 USD  25.97%

Haut 181 USD

Bas 110 USD

Basé sur 19 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

19 ratings

14

Achat

5

Maintien

0

Vente

Score Technique

By Trading Central

92.4 / 103.5Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

367 / 380Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac